Similar Papers

Paper Title
Journal
Date
Author
Cytokine Release Syndrome (CRS) Is Not Required for CAR-T Cell Efficacy in Aggressive Large B-NHL
Shakthi Bhaskar ... Olalekan O Oluwole
Blood | VOL. 140
Shakthi Bhaskar, et. al.Shakthi Bhaskar ... Olalekan O Oluwole
15 Nov 2022
Promoter usage regulating the surface density of CAR molecules may modulate the kinetics of CAR-T cells in vivo
Jin-Yuan Ho ... Jianqiang Li
Molecular therapy. Methods & clinical development | VOL. 21
Jin-Yuan Ho, et. al.Jin-Yuan Ho ... Jianqiang Li
13 Mar 2021
Key Findings from a Transformative Quality Improvement Initiative on Advancing CAR T-Cell Treatment in Non-Hodgkin Lymphoma
Manali K Kamdar ... Shelby Sullivan
Blood | VOL. 142
Manali K Kamdar, et. al.Manali K Kamdar ... Shelby Sullivan
28 Nov 2023
Shortening the ex vivo culture of CD19-specific CAR T-cells retains potent efficacy against acute lymphoblastic leukemia without CAR T-cell-related encephalopathy syndrome or severe cytokine release syndrome.
Sanfang Tu ... Lenghe Zhang
American Journal of Hematology | VOL. 94
Sanfang Tu, et. al.Sanfang Tu ... Lenghe Zhang
02 Oct 2019
View more papers

More From: Transplantation and Cellular Therapy

Paper Title
Journal
Date
Author
Pediatric Transplant and Cellular Therapy Consortium RESILIENT Conference on Pediatric Chronic Graft-versus-Host Disease Survivorship after Hematopoietic Cell Transplantation: Part II. Organ Dysfunction and Immune Reconstitution Considerations for children with chronic GVHD after Hematopoietic Cell Transplantation.
Saldaña Bj Dávila ... K M Williams
Transplantation and cellular therapy | VOL. -
Saldaña Bj Dávila, et. al.Saldaña Bj Dávila ... K M Williams
22 Jan 2025
Prolonged neurologic symptoms following immune effector cell-associated neurotoxicity syndrome in patients with large B cell lymphoma treated with chimeric antigen receptor-modified T cell therapy.
Luke Maillie ... Daniel J Landsburg
Transplantation and cellular therapy | VOL. -
Luke Maillie, et. al.Luke Maillie ... Daniel J Landsburg
21 Jan 2025
Low Survival Due to Higher Risk of Relapse and Nonrelapse Mortality After Allogeneic HSCT in ATL Compared with AML and ALL.
Shohei Tomori ... Makoto Yoshimitsu
Transplantation and cellular therapy | VOL. -
Shohei Tomori, et. al.Shohei Tomori ... Makoto Yoshimitsu
17 Jan 2025
Refining Risk Stratification for B-cell Precursor Adult Acute Lymphoblastic Leukemia Treated With a Pediatric-inspired Regimen by Combining IKZF1 Deletion and Minimal Residual Disease.
Shiyu Deng ... Hongsheng Zhou
Transplantation and cellular therapy | VOL. -
Shiyu Deng, et. al.Shiyu Deng ... Hongsheng Zhou
09 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.